Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EPS (Weighted Average and Diluted) (2020 - 2025)

Pulmonx (LUNG) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.34 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 5.56% to -$0.34 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.41, a 4.08% increase, with the full-year FY2024 number at -$1.44, up 10.0% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.34 for Q3 2025 at Pulmonx, up from -$0.38 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.28 in Q3 2021 to a low of -$0.43 in Q1 2022.
  • A 5-year average of -$0.37 and a median of -$0.36 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 94.15% in 2021; the steepest drop was 105.02% in 2021.
  • Pulmonx's EPS (Weighted Average and Diluted) stood at -$0.36 in 2021, then dropped by 5.56% to -$0.38 in 2022, then grew by 5.26% to -$0.36 in 2023, then grew by 8.33% to -$0.33 in 2024, then dropped by 3.03% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EPS (Weighted Average and Diluted) are -$0.34 (Q3 2025), -$0.38 (Q2 2025), and -$0.36 (Q1 2025).